Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA2 Will give Cronos #1 market share3 in the largest adult-use cannabis market in Europe Enables borderless product strategy, leveraging investments in genetics, R&D, and product development TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cr ...

Cannabis Stocks in Canada: December 2025 Investment GuideThe Canadian cannabis sector enters December 2025 with renewed attention from both traders and long-term investors. Market conditions have remained unpredictable this year, yet several leading companies continue showing resilience and strategic progress. The industry still faces slower domestic growth, tighter financing conditions, and heavy price competition. However, many operators are building stronger platforms, expanding international footprints, ...

Core Insights - Cronos Group Inc. achieved record levels of consolidated net revenue, gross profit, and Adjusted EBITDA in Q3 2025, with net revenue increasing by 9% quarter-over-quarter and 6% year-over-year [1][2] - The company reported record-high net revenue in Israel, where its PEACE NATURALS brand remains the number one cannabis brand [1][2] - Cronos Group maintains a strong balance sheet with $824 million in total cash and cash equivalents and short-term investments [1][3] Financial Performance - Net revenue for Q3 2025 was $36.3 million, an increase of $2.1 million from Q3 2024, primarily driven by higher cannabis flower sales in Israel and cannabis extract sales in Canada [10] - Gross profit for Q3 2025 was $18.3 million, up $14.7 million from Q3 2024, attributed to lower inventory step-up costs and higher average sales prices [10][7] - Adjusted EBITDA improved to $5.7 million in Q3 2025, an increase of $11.7 million from Q3 2024, driven by higher gross profit and lower operating expenses [10][7] Market Position - The Spinach brand ended Q3 2025 as the second most popular brand in Canada, holding a 4.5% total market share, and ranked 1 in edibles with a 19.7% market share [11][12] - PEACE NATURALS continues to be the top-performing brand in Israel, achieving record net revenue and sales volume in Q3 2025 [15][16] - International results outside of Israel were modest due to shipment timing, with expectations for second-half performance to align closely with the first half [16] Brand and Product Updates - The Spinach brand launched new products, including SOURZ by Spinach Fully Blasted gummies and limited-edition flavors, reinforcing its leadership in innovative cannabis edibles [12] - Cronos Group's expansion of Cronos GrowCo is complete, with sales from the expansion expected to fuel growth in 2026 [17] - The company introduced new strains under the PEACE NATURALS brand in Israel, reflecting its advanced genetic breeding program and cultivation capabilities [15]

Cannara Biotech Conference Summary Company Overview - **Company Name**: Cannara Biotech Inc. - **Stock Symbol**: LOVE (TSXV) - **Industry**: Canadian Cannabis - **Founded**: 2018 - **Headquarters**: Quebec, Canada - **Facilities**: Operates over 1.6 million square feet across two fully owned facilities in Quebec [2][5] Core Business and Market Position - Cannara Biotech is a vertically integrated cannabis company focused on producing premium-grade cannabis at scale, emphasizing profitability, innovation, and long-term value creation [2][4] - Currently the **seventh largest producer** in Canada by sales and **second largest** in Quebec, with a **12.8% market share** in Quebec, up from 9.7% a year ago [5][17] - Annualized production run rate is approximately **50,000 kilograms** (50 million grams) [5][6] Financial Performance - **Q3 2025**: Best quarterly financial results in the company's history - **Nine months of 2025**: - Net revenue: **$80 million** - Gross profit: **$32.7 million** - Gross margin: **41%**, with steady quarter-over-quarter increases [9][10] - Adjusted EBITDA: **$20.7 million** (26% of revenues) [10] - Net income: **$9.8 million**, a **53% increase** from the previous year [10] - **Cash Flow**: Generated **$17.2 million** in operating cash flow and **$12.3 million** in free cash flow in the first nine months of 2025 [11] Operational Highlights - Achieved a **26% increase** in capacity over the past year without additional capital costs [6][9] - Vertical integration allows full control over the cannabis supply chain, enhancing quality and efficiency [7][24] - Upcoming launch of a new vape category in Quebec, with **20% retail shelf space** already secured [8][17] Competitive Advantages - Strong operational platform with a focus on premium quality, scalable operations, and cost leadership [8][9] - Access to Quebec's low electricity rates of **$0.059 per kilowatt**, significantly lower than other provinces [26] - High barriers to entry in Quebec due to strict regulations on sales and marketing, allowing Cannara to thrive without heavy promotional activities [26][27] Strategic Initiatives - Plans for a **$10 million investment** in a new dedicated processing center to support growth and expand capacity to **100,000 kilograms** annually [16][24] - Focus on internal growth rather than external acquisitions, emphasizing operational discipline and quality [25][27] Market Trends and Outlook - The Canadian cannabis market is experiencing a shift, with a **41% surge** in estimated retail sales year-over-year, positioning Cannara as a leader in growth [16][17] - The company is well-prepared to meet unserved demand and capitalize on upcoming market opportunities, particularly in the vape segment [8][17] Conclusion - Cannara Biotech is positioned as a dominant player in the Canadian cannabis market, with a strong financial performance, operational efficiencies, and a clear growth strategy focused on quality and innovation [2][9][27]

Core Insights - The U.S. cannabis industry is rapidly maturing with larger markets and more efficient operators, despite ongoing federal restrictions on full legalization [1] - Federal policy changes are gradually occurring, indicating a potential long-term shift in the cannabis landscape [2] - State-level leaders are crucial for monitoring growth and investment opportunities in the cannabis sector [1][23] Federal Legalization Efforts - Cannabis remains illegal federally, but the Department of Justice is considering rescheduling it from Schedule I to Schedule III, which would acknowledge its medical use and lower abuse risk classification [2] - This rescheduling would not legalize recreational use but would ease research restrictions and reduce tax burdens under Section 280E [2] Banking Reform - The SAFER Banking Act aims to normalize banking for cannabis businesses, reducing cash usage and improving transparency [4] - This reform would provide legal protection for banks, allowing more institutions to serve the cannabis industry, thus lowering costs and enhancing capital access for operators [4] Growth Projections - Cannabis sales are projected to reach approximately $31.4 billion in 2024, with steady double-digit growth expected into 2025 [5] - By 2030, total sales are anticipated to exceed $67 billion, with some estimates reaching nearly $87 billion by 2035, contingent on expanded legalization and consumer shifts from the illicit market [5] State-Level Success Stories - **Michigan**: Market surpassed $3 billion in 2024, with strong demand despite falling prices due to competition [6] - **Missouri**: Sales reached $1.46 billion in 2024, driven by streamlined licensing and moderate taxes [7] - **Illinois**: Sales exceeded $2 billion in 2024, with tax revenues over $490 million, supported by social equity programs and strong urban demand [8] - **New Jersey**: Revenues surpassed $2 billion, benefiting from early access for medical operators [9] - **Florida**: Medical-only market with nearly 900,000 registered patients, showing significant sales potential [10] - **New York**: Sales on track to reach the billion-dollar mark, with improving licensing and supply chains [11] Tax Revenues and Community Impact - Since 2014, adult-use states have collected nearly $25 billion in tax revenue, supporting education, public health, and social equity initiatives [12] - Legal markets reduce illicit activity and provide consumers with tested and labeled products, benefiting communities through job creation and reinvestment [12] Future Considerations - Federal rescheduling and the SAFER Banking Act could significantly improve industry fundamentals [13] - State ballot measures and legislative sessions will influence growth trajectories, with tax debates being crucial for margins and expansion [13] Leading Companies - **Trulieve Cannabis Corp.**: Dominates Florida's medical market with over 190 dispensaries, reporting billions in annual revenue [15] - **Curaleaf Holdings Inc.**: Operates over 150 dispensaries across high-growth states, with strong revenue growth exceeding a billion dollars [17] - **Green Thumb Industries Inc.**: Operates more than 90 dispensaries, known for strong consumer brands and solid revenues above $1 billion annually [19][20] Investor Considerations - Investors should focus on efficient operators, evaluate tax structures, and consider municipal support [22] - Strong brands with consistent quality are likely to gain market share, and balance sheets will be critical post-280E reform [22]

Industry Overview - The U.S. cannabis industry is evolving with increasing legalization momentum and rising consumer demand [1][14] - Despite challenges such as oversupply and price compression, leading operators are positioning for future growth [1][14] - Multi-state operators with strong market share are expanding while maintaining financial discipline [1][14] Company Highlights Trulieve Cannabis Corp. (TCNNF) - Trulieve is one of the largest cannabis operators in the U.S., with over 190 dispensaries, primarily in Florida [3][5] - The company has a vertically integrated model, producing and selling a variety of cannabis products [3][6] - Recent financials show strong quarterly revenue and profitability, with effective cost-control strategies [5][6] Glass House Brands Inc. (GLASF) - Glass House operates large-scale greenhouses and a network of dispensaries in California, focusing on sustainable cultivation [7][9] - The company has maintained steady quarterly revenue and improved gross margins despite competitive pricing pressures [9] - Its cultivation capacity positions it as a cost leader in the U.S. market [7][9] Verano Holdings Corp. (VRNOF) - Verano operates over 140 dispensaries across 13 states, with a strong presence in Illinois, Florida, and New Jersey [10][11] - The company emphasizes quality control and cost efficiency through its vertically integrated operations [11][13] - Recent financial performance shows modest revenue growth and improved operating margins, despite industry challenges [13]

Core Insights - MJBizCon and Budist are launching the MJBowl, a bi-coastal competition to highlight the Most Valuable Products (MVP) from California and New York across five categories, with winners announced on December 4 [1][5] - The competition runs from August 14 to October 3, 2025, and is open to licensed cannabis companies in the respective states [2] - Judging will be conducted by Budist's panel of critics using a standardized scoring rubric to ensure credibility, with winning brands featured in consumer judging kits [3][4] Industry Context - The MJBowl aims to bridge the gap between East and West cannabis markets, promoting product excellence and national recognition for the cannabis industry [5] - Budist is positioned as a professional review platform, enhancing transparency and community engagement in cannabis product evaluations [8] - MJBiz is recognized as a leading B2B resource for the cannabis industry, producing the largest cannabis trade show, MJBizCon, which has been consistently ranked among the top trade shows in the U.S. [7]

Industry Overview - Canadian cannabis stocks are gaining momentum as the U.S. cannabis market is projected to reach nearly $45 billion by 2025, with legal sales expanding in over 20 states [1] - Renewed interest in federal reform is evident, with lawmakers pushing for rescheduling and broader legalization, despite local regulatory challenges [1] - Canadian firms with U.S. exposure are expected to benefit from these developments, leading to increased investor optimism [1] Company Highlights - **Sundial Growers Inc. (SNDL)** has transformed into a diversified cannabis and liquor operator, expanding its retail presence in the Southeastern U.S. and managing dozens of dispensaries [5][8] - For Q1 2025, Sundial reported net revenue exceeding $200 million, with significant gross profit growth and improved operational efficiency, despite still reporting an operating loss [8] - **Cronos Group Inc. (CRON)** has adopted a partnership strategy to gain U.S. exposure, allowing it to distribute branded products without direct ownership of retail stores [9] - In Q1 2025, Cronos saw a meaningful revenue increase, with gross profit more than doubling year-over-year and adjusted earnings turning positive for the first time in several quarters [11] - **High Tide Inc. (HITI)** operates the largest non-franchised cannabis retail chain in Canada and has a strong e-commerce presence in the U.S. [12] - The company reported over 10% revenue growth in Q2 2025, maintaining positive adjusted EBITDA for 21 consecutive quarters and expanding its store count to over 200 [14] Investment Outlook - August 2025 brings renewed interest in the cannabis sector, with Sundial, Cronos, and High Tide showing distinct strengths and operational momentum [15] - Each company demonstrates resilience and strategic growth, making them worthy of consideration for investors looking to tap into North America's cannabis potential [16]

Core Insights - Cronos Group Inc. reported a 28% year-over-year increase in net revenue for Q1 2025, reaching $32.3 million, with a 33% increase on a constant currency basis [1][11] - The company maintains a strong balance sheet with $838 million in total cash and cash equivalents and short-term investments [1] - PEACE NATURALS remains the leading cannabis brand in Israel, achieving record net revenue and market share [3][19] Financial Performance - Net revenue for Q1 2025 was $32,262 thousand, up from $25,288 thousand in Q1 2024, marking a $6,974 thousand increase [6][11] - Gross profit increased to $13,734 thousand in Q1 2025, a rise of $9,251 thousand from Q1 2024, resulting in a gross margin of 43% compared to 18% in the previous year [6][8] - Net income for Q1 2025 was $7,723 thousand, a significant improvement of $10,207 thousand from a loss of $2,484 thousand in Q1 2024 [8][11] Market Position and Brand Performance - The Spinach brand ranked as the second most popular brand in Canada with a 4.6% market share and third in the flower category with a 5.1% market share [13] - SOURZ by Spinach captured a 20% market share in the gummy category, making it the best-selling gummy brand in Canada [14] - Lord Jones Chocolate Fusions™ achieved a 9.6% market share, ranking as the third best-selling chocolate cannabis edible brand in Canada [16] Strategic Initiatives - Cronos GrowCo's expansion is on track for completion in Q2 2025, which is expected to significantly increase cultivation capacity and meet growing demand [2][22] - The company has authorized a share repurchase program of up to $50 million, expected to commence on May 14, 2025 [10] - New product launches in Q1 2025 include strain-specific cannabis oils under the PEACE NATURALS brand, aimed at enhancing product offerings in international markets [19][20] Regulatory Environment - An anti-dumping duty of up to 165% on Canadian medical cannabis imports into Israel was proposed but later vetoed, although the Ministry of Economy intends to pursue the duty process [23]